Free tool
FAERS Monitor: Maxitrol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050065 or its brand name (Maxitrol, Dexamethasone, Neomycin Sulfate, Polymyxin B Sulfate). Reports on generic versions are filed under their own applications.
Reports
1,087
Serious
663
61% of reports
Hospitalization
229
Death reported
50
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain92
- eye irritation80
- vision blurred70
- ocular hyperaemia60
- off label use58
- pain52
- visual impairment52
- drug ineffective48
- headache46
- fatigue42
- dyspnoea39
- condition aggravated37
- nausea36
- anxiety35
- intraocular pressure increased35
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 14 |
| 2008 | 7 |
| 2009 | 12 |
| 2010 | 21 |
| 2011 | 5 |
| 2012 | 21 |
| 2013 | 30 |
| 2014 | 33 |
| 2015 | 44 |
| 2016 | 104 |
| 2017 | 56 |
| 2018 | 89 |
| 2019 | 94 |
| 2020 | 106 |
| 2021 | 58 |
| 2022 | 77 |
| 2023 | 95 |
| 2024 | 77 |
| 2025 | 77 |
| 2026 | 53 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,072 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 35 | 53.1 | 38.3 | 1,735 |
| eye painSignal | 92 | 31.6 | 26.0 | 2,699 |
| eye irritationSignal | 80 | 26.9 | 21.8 | 1,974 |
| ocular hyperaemiaSignal | 60 | 24.5 | 19.1 | 1,330 |
| vision blurredSignal | 70 | 9.9 | 7.9 | 552 |
| visual impairmentSignal | 52 | 8.1 | 6.2 | 319 |
| anxietySignal | 35 | 2.4 | 1.7 | 27 |
| condition aggravatedSignal | 37 | 2.4 | 1.7 | 28 |
| pain | 52 | 1.6 | 1.3 | 13 |
| headache | 46 | 1.4 | 1.1 | 5 |
| dyspnoea | 39 | 1.3 | 1.0 | 3 |
| off label use | 58 | 1.3 | 1.0 | 3 |
| fatigue | 42 | 1.0 | 0.8 | 0 |
| nausea | 36 | 0.9 | 0.6 | 0 |
| drug ineffective | 48 | 0.7 | 0.5 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.